Familial hypertrophic cardiomyopathy: clinical features, molecular genetics and molecular genetic testing.

Abstract

Hypertrophic cardiomyopathy is a Mendelian disease characterized by cardiac hypertrophy. It has a prevalence of 1:500 individuals and is the most common cause of sudden death in the young. Other complications include heart failure and the need for heart transplantation. Hypertrophic cardiomyopathy is due to sarcomeric gene mutations, however, phenocopies with myocardial hypertrophy can be due to triplet-repeat syndromes (Friedreich ataxia and myotonic dystrophy), mitochondrial and metabolic diseases. In a peculiar form associated with Wolf-Parkinson-White syndrome, the disease is caused by mutations in the gamma2 regulatory subunit of the AMP-activated protein kinase gene, leading to a glycogen storage cardiomyopathy. In spite of the growing knowledge about the molecular basis of hypertrophic cardiomyopathy, very little is still known about the genotype-phenotype correlations and their clinical implications. In this review, the clinical and molecular genetics of hypertrophic cardiomyopathy are described.

• Authors: Matthew R G Taylor, Elisa Carniel, Luisa Mestroni
• Journal: Expert review of molecular diagnostics (Expert Rev Mol Diagn) Vol. 4 Issue 1 Pg. 99-113 (Jan 2004) ISSN: 1473-7159 [Print] England
• PMID: 14711353 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)
• Copyright: Copyright Future Drugs Ltd.

Chemical References

• DNA, Mitochondrial

Topics

• Animals
• Cardiomyopathy, Hypertrophic, Familial (diagnosis, genetics, metabolism, therapy)
• DNA, Mitochondrial (genetics)
• Genetic Testing
• Humans
• Mutation (genetics)